Frontiers in Immunology最新文献

{"title":"The transcription repressor Bach2 is required for maintaining the B-1 cell population by regulating self-renewal.","authors":"Seung-Gen Oh, Jeonghyun Noh, Eunkyeong Jang, Jeehee Youn","doi":"10.3389/fimmu.2025.1553089","DOIUrl":"10.3389/fimmu.2025.1553089","url":null,"abstract":"<p><p>B-1 cells are a distinct lineage of tissue-resident B cells with crucial roles in innate immunity and tissue homeostasis. Mature B-1 cell pools are mostly maintained by self-renewal in their peripheral niches, in a process that is largely uncharacterized. Here, we investigated the role of the transcription repressor Bach2 in maintaining the B-1 cell pool. We found that B-1 cell numbers and antibody responses were dramatically reduced in adult mice bearing a B cell-specific <i>Bach2</i> deletion, although the proportions of B-1 progenitors in early neonatal life were unaffected. Cells taken from the fetal liver or bone marrow of <i>Bach2</i>-deleted mice were defective in reconstituting the B-1 cell pool in the peritonea of <i>Rag2^-/-</i> hosts, and peritoneal B-1 cell transplants from adult <i>Bach2</i>-deleted mice failed to sustain their numbers in the host's peritoneum. The mutant B-1 cells proliferated normally <i>in vivo</i> but were more apoptotic. They also expressed the reduced level of the self-renewal factor Bmi1. These results indicate that Bach2 deficiency does not affect the development of B-1 progenitors in fetal liver and bone marrow but impairs the self-renewal of mature B-1 cells in peripheral tissues, which is caused by increased apoptosis. Thus, this study suggests that a cell-autonomous function of Bach2 is crucial for maintaining a stable population size of B-1 cells in their peripheral niches.</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1553089"},"PeriodicalIF":5.7,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11958198/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of prognostic subtypes and the role of FXYD6 in ovarian cancer through multi-omics clustering.","authors":"Boyi Ma, Chenlu Ren, Yun Gong, Jia Xi, Yuan Shi, Shuhua Zhao, Yadong Yin, Hong Yang","doi":"10.3389/fimmu.2025.1556715","DOIUrl":"10.3389/fimmu.2025.1556715","url":null,"abstract":"<p><strong>Background: </strong>Ovarian cancer (OC), as a malignant tumor that seriously endangers the lives and health of women, is renowned for its complex tumor heterogeneity. Multi-omics analysis, as an effective method for distinguishing tumor heterogeneity, can more accurately differentiate the prognostic subtypes with differences among patients with OC. The aim of this study is to explore the prognostic subtypes of OC and analyze the molecular characteristics among the different subtypes.</p><p><strong>Methods: </strong>We utilized 10 clustering algorithms to analyze the multi-omics data of OC patients from The Cancer Genome Atlas (TCGA). After that, we integrated them with ten different machine-learning methods in order to determine high-resolution molecular subgroups and generate machine-learning-driven characteristics that are both resilient and consensus-based. Following the application of multi-omics clustering, we were able to identify two cancer subtypes (CSs) that were associated with the prognosis. Among these, CS2 demonstrated the most positive predictive outcome. Subsequently, five genes that constitute the machine learning (ML)-driven features were screened out by ML algorithms, and these genes possess a powerful predictive ability for prognosis. Subsequently, the function of FXYD Domain-Containing Ion Transport Regulator 6 (FXYD6) in OC was analyzed through gene knockdown and overexpression, and the mechanism by which it affects the functions of OC was explored.</p><p><strong>Results: </strong>Through multi-omics analysis, we ascertained that the high-risk score group exhibits a poorer prognosis and lack of response to immunotherapy. Moreover, this group is more prone to display the \"cold tumor\" phenotype, with a lower likelihood of benefiting from immunotherapy. FXYD6, being a crucial differential molecule between subtypes, exerts a tumor-promoting effect when knocked down; conversely, its overexpression yields an opposite outcome. Additionally, we discovered that the overexpression of FXYD6 can induce ferroptosis in OC cells, implying that a low level of FXYD6 in OC cells can safeguard them from ferroptosis. Insightful and more precise molecular categorization of OC can be achieved with a thorough examination of multi-omics data. There are significant consequences for clinical practice stemming from the discovery of risk scores since they provide a useful tool for early prognosis prediction as well as the screening of candidates for immunotherapy.</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1556715"},"PeriodicalIF":5.7,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11958163/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ZNFX1: a multifunctional modulator of the innate immune response.","authors":"Li Yi Cheng, Roy Parker","doi":"10.3389/fimmu.2025.1564628","DOIUrl":"10.3389/fimmu.2025.1564628","url":null,"abstract":"<p><p>Recent research has identified ZNFX1 as a critical modulator of the innate immune response. Individuals with loss of function mutations in ZNFX1 have chronic inflammation and increased susceptibility to various pathogens. Several potential functions of ZNFX1 have been proposed, including binding double-stranded RNA to activate antiviral innate immunity, inhibiting the NLRP3 inflammasome, and regulating the stability of host mRNAs. Notably, homologs of ZNFX1 are implicated in innate immunity across a wide range of species, including contributing to transgenerational epigenetic inheritance of small RNA-based defense in <i>C. elegans</i>. In this review, we discuss the significance of ZNFX1 and explore the potential underlying mechanisms that govern its diverse functions.</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1564628"},"PeriodicalIF":5.7,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959080/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A high content clonogenic survival drug screening identifies maytansine as a potent radiosensitizer for meningiomas.","authors":"Jinxiu Yu, Jiaojiao Deng, Leihao Ren, Lingyang Hua, Tianqi Wu, Yi Hui, Chunlin Shao, Ye Gong","doi":"10.3389/fimmu.2025.1557165","DOIUrl":"10.3389/fimmu.2025.1557165","url":null,"abstract":"<p><strong>Purpose: </strong>Radiation resistance significantly hinders the efficacy of radiotherapy for meningiomas, posing a primary obstacle. The clinical inadequacy of therapeutic drugs and radiosensitizers for treating meningiomas further exacerbates the challenge. Therefore, the aim of this study was to identify potential radiosensitizers for treating meningiomas.</p><p><strong>Methods: </strong>A high content clonogenic survival drug screening was employed to evaluate 166 FDA-approved compounds across varied concentration ranges. Cell viability, apoptosis, and radiosensitization were assessed using CCK-8 assays, Annexin V-FITC/PI assays and standard colony formation assays. Transcriptome sequencing, immunofluorescence and cell cycle experiments were conducted to assess transcriptional profile, DNA double-strand break damage and cell cycle distribution. Finally, the radiosensitizing effect of Maytansine was assessed <i>in vivo</i> through subcutaneous tumor implantation in nude mice.</p><p><strong>Results: </strong>The proportion of maytansine exhibiting SRF≥1.5 within the detectable concentration range was 100%. CCK-8 assay indicated the IC50 values of maytansine for IOMM-Lee and CH157 were 0.26 ± 0.06 nM and 0.31 ± 0.01 nM, respectively. Standard clonogenic survival assays and Annexin V-FITC/PI assays revealed maytansine had a notable radiosensitizing effect on meningioma cells. Transcriptome sequencing analysis demonstrated that maytansine can modulate cell cycle and DNA damage repair. Immunofluorescence analysis of γ-H2AX and cell cycle experiments demonstrated that Maytansine enhances DNA double-strand breaks and induces G2/M phase arrest. Moreover, <i>in vivo</i> studies had indicated that Maytansine augments the therapeutic efficacy of radiotherapy.</p><p><strong>Conclusion: </strong>This study highlighted the potential of maytansine as a potent inhibitor and radiosensitizer for meningiomas by inducing G2/M phase cell cycle arrest and enhancing DNA double-strand break damage. These findings opened up a promising path in the development of radiosensitizers aimed at treating this condition.</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1557165"},"PeriodicalIF":5.7,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959303/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Vector-based gene delivery in cancer immunotherapy.","authors":"Ning Cheng, Xiaoyue Yang, Dan Chen, Chun Xu","doi":"10.3389/fimmu.2025.1587359","DOIUrl":"10.3389/fimmu.2025.1587359","url":null,"abstract":"","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1587359"},"PeriodicalIF":5.7,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959163/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of two different variants in the <i>MAGT1</i> gene on B cell subsets, platelet function, and cell glycome composition.","authors":"Lucía Del Pino Molina, Elena Monzón Manzano, Carla Gianelli, Luz Yadira Bravo Gallego, Javier Bujalance Fernández, Paula Acuña, Yolanda Soto Serrano, Keren Reche Yebra, María Bravo García-Morato, Elena Sánchez Zapardiel, Elena G Arias-Salgado, Rebeca Rodríguez Pena, Nora Butta, Eduardo López Granados","doi":"10.3389/fimmu.2025.1547808","DOIUrl":"10.3389/fimmu.2025.1547808","url":null,"abstract":"<p><strong>Introduction: </strong>X-linked immunodeficiency with magnesium defect, Epstein-Barr virus (EBV) infection and neoplasia (XMEN) disease is caused by hemizygous loss of function (LOF) gene variants in <i>MAGT1</i>. MAGT1 is a plasma membrane transporter of magnesium (Mg²⁺) that plays a relevant role in immune responses and acts as a second messenger in intracellular signaling, but also it is involved in the glycosylation of proteins. Here we report two gene variants in the <i>MAGT1</i> gene from two different families with XMEN disease. A <i>de novo</i> variant c.97_98 delinsC affecting one member of one family and three members of a second family presented the hemizygous variant c.80``3G>A, p.Trp268Ter, causing a premature stop codon.</p><p><strong>Methods: </strong>We performed a functional validation of these two variants in the <i>MAGT1</i> gene and their association with decreased NKG2D expression, uncontrolled EBV viremia, and the development of lymphoma-associated complications in three members of the same family.</p><p><strong>Results: </strong>We analyzed the B-cell compartment, we found that the B-cell expansion is driven by immature/transitional (CD5^- and CD5⁺) and naïve B cells. The patients presented normal absolute counts of memory B-cells (MBCs) but with differences between them in the diversity of immunoglobulin heavy chain (IgH) isotype distribution in MBC, and diverse reduction of plasma cells. We also explored the alterations of platelets due to hemorrhagic events and a history of thrombocytopenia in some of our patients. We found diminished TRAP-induced calcium flux, P-selectin and CD63 exposure in XMEN patients, while when platelets from patients were stimulated ADP the results were similar to healthy controls. Finally, we explored the glycosylation pattern in platelets and lymphocytes. Our results suggest that different variants in <i>MAGT1</i> gene might result in different effects on NK cells and platelet glycome composition.</p><p><strong>Discussion: </strong>Here, we report the two different outcomes regarding EBV-driven lymphoproliferative complications, the family with three members affected that developed the malignant lymphoproliferative complications before XMEN diagnosis, and the patient with early diagnose of MAGT1 deficiency due to EBV viremia. As a recommendation, XMEN disease should be ruled out in males with impaired clearance of EBV-infection and EBV-driven lymphoproliferative complications.</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1547808"},"PeriodicalIF":5.7,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11958192/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging immunotherapies in osteosarcoma: from checkpoint blockade to cellular therapies.","authors":"Zhiwei Han, Guomin Chen, Dongchen Wang","doi":"10.3389/fimmu.2025.1579822","DOIUrl":"10.3389/fimmu.2025.1579822","url":null,"abstract":"<p><p>Osteosarcoma remains a highly aggressive bone malignancy with limited therapeutic options, necessitating novel treatment strategies. Immunotherapy has emerged as a promising approach, yet its efficacy in osteosarcoma is hindered by an immunosuppressive tumor microenvironment and resistance mechanisms. This review explores recent advancements in checkpoint blockade, cellular therapies, and combination strategies aimed at enhancing immune responses. We highlight key challenges, including tumor heterogeneity, poor immune infiltration, and the need for predictive biomarkers. By integrating immunotherapy with chemotherapy, radiotherapy, and targeted therapy, emerging approaches seek to improve treatment outcomes. This review provides a comprehensive analysis of the evolving landscape of osteosarcoma immunotherapy, offering insights into future directions and potential breakthroughs. Researchers and clinicians will benefit from understanding these developments, as they pave the way for more effective and personalized therapeutic strategies in osteosarcoma.</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1579822"},"PeriodicalIF":5.7,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11958959/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased long-term central memory T cells in patients with retreatment pulmonary tuberculosis.","authors":"Xin Yao, Haomin Cai, Jianxia Chen, Fangyong Yu, Xiaocui Wu, Yarong Shi, Yang Hu, Yuyan Xu, Qinghua Xu, Zhonghua Liu","doi":"10.3389/fimmu.2025.1545537","DOIUrl":"10.3389/fimmu.2025.1545537","url":null,"abstract":"<p><strong>Background: </strong>T cells are crucial in controlling Mycobacterium tuberculosis infection and disease progression. Nevertheless, the specific functions and changes of T lymphocyte subsets in retreatment tuberculosis remain poorly understand. The study aims to identify the changes in T lymphocyte subsets and the immunoprotective effect of T_CM in retreatment tuberculosis.</p><p><strong>Method: </strong>We collected venous blood from the participants and assessed using flow cytometry. Univariate analysis and regression model were used to evaluate the changes of T lymphocyte subsets and key subsets in retreatment tuberculosis.</p><p><strong>Results: </strong>In the study, while the frequencies of CD4 and CD8 T cells were similar between primary and retreatment patients, retreatment patients exhibited a significant increase in T_CM (<i>P</i> < 0.05), which may represent a protective factor for retreatment (adjusted OR=0.926, 95%CI: 0.860-0.996, <i>P</i> < 0.05) (adjusted OR=0.951, 95%CI: 0.912-0.992, <i>P</i><0.05). Furthermore, T_CM significantly increased in retreatment patients who achieved cure (<i>P</i> < 0.05), though were similar between the cure and no-cure for primary patients; The potentially protective effect of T_CM in patients with repeated infection may possibly contribute by improving the efficacy of retreatment chemotherapy (adjusted OR=0.803, 95%CI: 0.677-0.953, <i>P</i> < 0.05) (adjusted OR=0.890, 95% CI: 0.812-0.976, <i>P</i><0.05), particularly in those with lung injury (adjusted OR=0.780, 95% CI: 0.635-0.957, <i>P</i>< 0.05) (adjusted OR=0.805, 95% CI: 0.660-0.983, <i>P</i><0.05).</p><p><strong>Conclusion: </strong>Development of adjunct immunotherapies for increasing T_CM responses may improve the efficacy of retreatment tuberculosis with existing and with novel chemotherapies.</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1545537"},"PeriodicalIF":5.7,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959053/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An updated review on immune checkpoint inhibitor-induced colitis: epidemiology, pathogenesis, treatment strategies, and the role of traditional Chinese medicine.","authors":"Huijing Dong, Yanmei Peng, Xinmeng Wang, Huijuan Cui","doi":"10.3389/fimmu.2025.1551445","DOIUrl":"10.3389/fimmu.2025.1551445","url":null,"abstract":"<p><p>Immune checkpoint inhibitor-induced colitis (irColitis) is a common and severe adverse reaction to immune checkpoint inhibitors (ICIs), significantly impacting the treatment outcomes and quality of life of cancer patients. Epidemiological studies indicate that the incidence of irColitis is associated with factors such as the type of ICIs, the patient's gender, age, and medical history. Although the exact pathophysiology remains unclear, irColitis is thought to be related to immune system activation and dysregulation, gut microbiota imbalance, and impaired epithelial barrier function. This review summarized the epidemiology, clinical presentation, diagnostic criteria, and pathogenesis of irColitis. Additionally, the standard and novel therapeutic strategies of irColitis, including corticosteroids, biologics, and gut microbiota interventions, more importantly the potential and application of Traditional Chinese Medicine (TCM). Future researches call for deeper mechanistic investigations, the development of biomarkers, and reveal the integration of TCM therapies within individual immunotherapy frameworks.</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1551445"},"PeriodicalIF":5.7,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955479/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pemphigoid disease model systems for clinical translation.","authors":"Marvin Tigges, Sören Dräger, Ilaria Piccini, Katja Bieber, Artem Vorobyev, Janin Edelkamp, Marta Bertolini, Ralf J Ludwig","doi":"10.3389/fimmu.2025.1537428","DOIUrl":"10.3389/fimmu.2025.1537428","url":null,"abstract":"<p><p>Pemphigoid diseases constitute a group of organ-specific autoimmune diseases characterized and caused by autoantibodies targeting autoantigens expressed in the skin and mucous membranes. Current therapeutic options are still based on unspecific immunosuppression that is associated with severe adverse events. Biologics, targeting the IL4-pathway or IgE are expected to change the treatment landscape of pemphigoid diseases. However, clinical studies demonstrated that targeting these pathways alone is most likely not sufficient to meet patient and healthcare partitioners expectations. Hence, model systems are needed to identify and validate novel therapeutic targets in pemphigoid diseases. These include pre-clinical animal models, <i>in vitro</i> and <i>ex vivo</i> model systems, hypothesis-driven drug repurposing, as well as exploitation of real-world-data. In this review, we will highlight the medical need for pemphigoid diseases, and in-depth discuss the advantages and disadvantages of the available pemphigoid disease model systems. Ultimately, we discuss how rapid translation can be achieved for the benefit of the patients.</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1537428"},"PeriodicalIF":5.7,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955494/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}